| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q |
| P698 | PubMed publication ID | 11083267 |
| P2093 | author name string | Andrews B | |
| Abeles M | |||
| Medsger TA Jr | |||
| Steen VD | |||
| Collier D | |||
| Wong WK | |||
| Varga J | |||
| White B | |||
| Furst DE | |||
| Martin RW | |||
| Seibold JR | |||
| Clements PJ | |||
| Barr W | |||
| Weinstein A | |||
| Mayes M | |||
| Weiner SR | |||
| Weisman M | |||
| Lally E | |||
| Wigley F | |||
| Hurwitz EL | |||
| Moreland L | |||
| P2860 | cites work | Factors predicting development of renal involvement in progressive systemic sclerosis | Q39343777 |
| Grasp pattern variations seen in the scleroderma hand | Q39398259 | ||
| The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time | Q39455773 | ||
| High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial | Q41671784 | ||
| Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis | Q41701251 | ||
| Preliminary criteria for the classification of systemic sclerosis (scleroderma) | Q54165663 | ||
| A note on a general definition of the coefficient of determination | Q56505617 | ||
| P433 | issue | 11 | |
| P921 | main subject | D-penicillamine | Q421239 |
| P304 | page(s) | 2445-2454 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial | |
| P478 | volume | 43 |
| Q37339012 | A "silent" course of normotensive scleroderma renal crisis: case report and review of the literature |
| Q58723092 | A Paradigmatic Interplay between Human Cytomegalovirus and Host Immune System: Possible Involvement of Viral Antigen-Driven CD8+ T Cell Responses in Systemic Sclerosis |
| Q44755169 | A longitudinal analysis of humor coping and quality of life in systemic sclerosis. |
| Q35878705 | A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-ph |
| Q51517488 | A novel approach to measuring skin elasticity in systemic sclerosis: results from a pilot study. |
| Q30359351 | A preliminary study of skin ultrasound in diffuse cutaneous systemic sclerosis: Does skin echogenicity matter? |
| Q90831203 | A quantitative method for measuring the changes of lung surface wave speed for assessing disease progression of interstitial lung disease |
| Q92587639 | An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups |
| Q47292923 | An Ultrasound Surface Wave Technique for Assessing Skin and Lung Diseases |
| Q28390528 | Animal models of systemic sclerosis: their utility and limitations |
| Q47835767 | Assessment of skin involvement in systemic sclerosis |
| Q33536943 | Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? |
| Q44147232 | Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group |
| Q35554404 | Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry |
| Q60309683 | B-type Natriuretic Peptide as a Marker of Different Forms of Systemic Sclerosis |
| Q37912251 | Biomarkers for skin involvement and fibrotic activity in scleroderma |
| Q37806663 | Biomarkers in the management of scleroderma: an update |
| Q37905787 | Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling |
| Q38825869 | Clinical Trial Design Issues in Systemic Sclerosis: an Update |
| Q55069247 | Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. |
| Q44213156 | Clinical trials for pediatric scleroderma |
| Q47839424 | Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis |
| Q34905661 | Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries. |
| Q35878701 | Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis |
| Q44285271 | Correlations between nailfold microangiopathy severity, finger dermal thickness and fingertip blood perfusion in systemic sclerosis patients |
| Q37301159 | Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials |
| Q34567929 | Current treatment options in systemic Sclerosis (Scleroderma). |
| Q40082697 | Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis |
| Q48515752 | Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study |
| Q90363927 | Drugs in phase I and phase II clinical trials for systemic sclerosis |
| Q53396252 | Editorial: genomic advances in systemic sclerosis: it is time for precision. |
| Q50623134 | Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. |
| Q92154864 | Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma |
| Q36733749 | Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study |
| Q37763779 | Evidence-based management of rapidly progressing systemic sclerosis |
| Q36040200 | Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients |
| Q41651775 | Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association? |
| Q34017756 | Hematopoietic cell transplantation for Crohn's disease; is it time? |
| Q33765551 | High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis |
| Q35925071 | High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study |
| Q37248942 | Histomorphometric analysis of cutaneous remodeling in the early stage of the scleroderma model |
| Q36960995 | Human autoimmune diseases are specific antigen-driven T-cell diseases: identification of the antigens |
| Q42426541 | Local skin gene expression reflects both local and systemic skin disease in patients with systemic sclerosis |
| Q35554342 | Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis |
| Q64119506 | Lysyl oxidase enzymes mediate TGF-β1-induced fibrotic phenotypes in human skin-like tissues |
| Q37003312 | Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis |
| Q36625804 | Measuring illness behavior in patients with systemic sclerosis |
| Q33354088 | Molecular subsets in the gene expression signatures of scleroderma skin |
| Q24618843 | My approach to the treatment of scleroderma |
| Q36154430 | Old medications and new targeted therapies in systemic sclerosis |
| Q36821503 | Outcome measures in systemic sclerosis: an update on instruments and current research |
| Q35977294 | Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis |
| Q47201744 | Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study |
| Q38100669 | Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects |
| Q45996905 | Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis. |
| Q35550480 | Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease |
| Q45995241 | Points to consider in renal involvement in systemic sclerosis. |
| Q92945989 | Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis |
| Q38801237 | Predictors of inpatient mortality in patients with systemic sclerosis: a case control study |
| Q64113861 | Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort |
| Q33665990 | Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis |
| Q38180018 | Quantitating skin fibrosis: innovative strategies and their clinical implications |
| Q33708349 | Quantitative assessment of scleroderma by surface wave technique |
| Q37590671 | Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria |
| Q36310765 | Rheumatic disease among Oklahoma tribal populations: a cross-sectional study |
| Q37620086 | Rheumatic manifestations of skin disease |
| Q40683161 | Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial |
| Q36951036 | Scleroderma renal crisis, still a life-threatening complication |
| Q37655603 | Scleroderma renal crisis: a rare but severe complication of systemic sclerosis |
| Q47650291 | Self-assessment of skin tightness severity by scleroderma patients |
| Q37324622 | Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials |
| Q82754205 | Serum N-terminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis? |
| Q51870089 | Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. |
| Q74452502 | Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis |
| Q40309151 | Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients |
| Q37265837 | Skin involvement in systemic sclerosis |
| Q37434973 | Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma |
| Q92353151 | Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study |
| Q92277815 | Sonoelastography for Skin Evaluation in Sclerodermic Patients |
| Q88091925 | Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis |
| Q38701990 | Strategy for treatment of fibrosis in systemic sclerosis: Present and future |
| Q40809160 | Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran |
| Q90243697 | Systemic sclerosis - multidisciplinary disease: clinical features and treatment |
| Q38059459 | Systemic sclerosis--challenges for clinical practice. |
| Q36758822 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q40002833 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q42099293 | The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis |
| Q37808133 | The Scleroderma Kidney: Progress in Risk Factors, Therapy, and Prevention |
| Q38752477 | The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters |
| Q38472289 | The correlation between durometer score and modified Rodnan skin score in systemic sclerosis |
| Q47583542 | The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis |
| Q37703398 | Thermography Improves Clinical Assessment in Patients with Systemic Sclerosis Treated with Ozone Therapy |
| Q90415563 | Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions |
| Q38966586 | Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). |
| Q89946091 | Ultrasound Surface Wave Elastography for Assessing Scleroderma |
| Q35169077 | Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis |
| Q52841896 | Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. |
| Q80772419 | [Scleroderma in childhood and adolescence. New aspects on classification, etiology and therapy] |
| Q80260010 | [Systemic sclerosis] |
Search more.